Over 50 Companies Invited to ICN Stem Cell Investor Conference

NEW YORK, NY--(Marketwired - Oct 12, 2015) - Investor Conference Network (ICN) announced today that over 50 private and publicly traded stem cell companies were invited to its upcoming conference in New York City, on October 26th and 27th at the 1st Annual Stem Cell Investor Conference.

The invitation only conference, has invited over 58 of the leading stem cell companies including 39 from the U.S., seven from Australia, three from Israel and twelve others internationally, to present in front of hundreds of Wall Street institutional investors in the first "stem-cell-only" financial conference of its kind.

"The larger the presenter attendance, the better the conference," stated Roland Rick Perry conference Chairman and managing director of Institutional Analyst Inc., which publishes the Stem Cell Stock Review. "We encourage institutional investors to call their portfolio companies listed below, to ensure their welcomed attendance and presentation."

2015 Invited List:

Actinogen Limited - Australia
Accurexa Inc.
AMAG Pharmaceuticals, Inc.
Antisense Therapeutics Ltd. Australia
Asterias Biotherapeutics, Inc.
Athersys, Inc.
Brainstorm Cell Therapeutics Inc.
BioLife Solutions, Inc.
bluebird bio, Inc.
Benitec Biopharma Limited - Australia
Bone Therapeutics SA - Belgium
BioRestorative Therapies, Inc.
BioTime, Inc.
Capricor Therapeutics, Inc.
Cord Blood America Inc.
Cellular Biomedicine Group Inc. - China
Cryo-Cell International, Inc.
Cellect Biomed Ltd. - Israel
Caladrius Biosciences, Inc.
China Cord Blood Corporation - China
Cortendo/Stonebridge - Sweden
American Cryostem Corporation
Neuralstem, Inc.
Cynata Therapeutics Limited - Australia
Cytori Therapeutics, Inc.
Fate Therapeutics, Inc.
Fibrocell Science, Inc.
Harvard Apparatus Regenerative Technology, Inc.
Harvard Bioscience Inc.
Cellular Dynamics International, Inc.
ImmunoCellular Therapeutics, Ltd.
International Stem Cell Corporation
Kiadis Pharma - Netherlands
Kadimastem Ltd. - Israel
Cesca Therapeutics Inc.
MiMedx Group, Inc.
Mesoblast Limited - Australia
Ocata Therapeutics, Inc.
Orthocell Limited - Australia
Organovo Holdings, Inc.
Orgenesis Inc.
Osiris Therapeutics, Inc.
Aratana Therapeutics, Inc.
ProtoKinetix Inc.
Pluristem Therapeutics, Inc. (PSTI) - Israel
ReNeuron Group plc (RENE.L) - United Kingdom
RepliCel Life Sciences Inc. (REPCF) - Canada
Regenicin, Inc. (RGIN)
Regenerx Biopharmaceuticals Inc. (RGRX)
Regeneus Ltd (RGS.AX) - Australia
Reprocell (4978) - Japan
RTI Surgical Inc. (RTIX)
Strongbridge Biopharma PLC (SBBP) - Sweden
IntelliCell BioSciences, Inc. (SVFC)
TiGenix N.V. (TGXSF) - Belgium
Vericel Corporation (VCEL)
Vitro Diagnostics, Inc. (VODG)
Verastem, Inc. (VSTM)
Intrexon Corporation (XON)

The 2015 Stem Cell Conference will be held at two separate NYC locations and is by invitation only with presentations from 9am to 5pm. Titled "Where Stem Cell Science, Meets Wall Street" the conference will feature presentations by CEOs and CFOs and expert panels moderated by industry leaders.

It is an opportunity for stem cell company management to meet the largest amount of Wall Street professionals' possible interested in stem cell science, ever assembled under one roof. This event is geared to investment bankers, buy- and sell-side investment analysts, fund managers and venture capital firms.

For conference details and to see a list of invited presenters, visit http://www.stemcellinvestorconference.com

To ensure optimal all-day institutional attendance, presentation schedules will only be released the day of the conference, at the conference entrance. A limited number of attendance tickets for $1,195 will be available on a first come first serve basis. Admission is complimentary for institutional investors and press.

Video Interviews:
Each presentation will be video taped and archived for later viewing at the Stem Cell Investor Conference website and at the Biotech Exec TV website, by FMW Media Works -- a leading financial broadcast provider. New To The Street will additionally be conducting "at conference" interviews with company executives to highlight late breaking news. 
http://www.biotechexectv.com
http://www.newtothestreet.com
Video scheduling is handled by Vincent Caruso at 631-465-0284

Printed Interviews:
Wall Street Analyzer (WSA) will also be available to conduct in-depth executive interviews. WSA's staff of writers and analysts goal, is to produce informative interviews that will help investors understand a companies' upside and provide company leadership vision.
http://wallstreetanalyzer.com/
Scheduling is handled by Juan Costello at 347-529-5734

Press Releases:
Each presenter receives a complimentary conference participation press release from NewsMediaWire the leading search optimized press release distribution service for news, photos and multimedia content from public and private corporations, non-profit organizations, colleges and universities, government agencies and other public sector organizations.
Contact Tom Speciale 561-852-2621

Sponsorships:
Sponsorship's include web and event and a full page in the Stem Cell Investor Conference Guide. There are also sponsorship opportunities for the lunch and cocktail party. Ideal for public company service providers.
Please call Xavier Franco for details 310-924-4088

About Stem Cell Investor Conference:
The Stem Cell Investor Conference brings together both publicly traded and privately held stem cell companies and introduces their management directly to Wall Street. It is the only conference of its kind and designed to provide a forum where only Stem Cell related companies, network with select members of the institutional investment community.

While there are many medical technology and biotech conferences held throughout year, the Stem Cell Investor Conference presents just stem cell companies. The conference is additionally inviting a broader base of professional investors from all segments of the micro-cap market (between $50 and $300 million) to participate, including aggressive hedge funds experienced at investing at the micro-cap level.

About FMW MediaWorks/NTTS:
Produced by FMW Mediaworks, "New To The Street" paves the way to the latest financial issues, offering a blend of business and financial services news reporting and in-depth interviews relating to new products, economic analysis and public company profiles. FMW Media Works Corp. a leading provider of business profiles and corporate special programming, and airs as paid-programming on select stations nationwide including The History Channel and A&E. reaching more than 95 million homes. Visit http://www.newtothestreet.com.

About NewMediaWire:
By delivering news announcements and promotions in real time to thousands of national newspapers, broadcast outlets, search engines, news aggregators, individual journalists, blogs & websites, NewMediaWire helps drive traffic back to the issuers' newsroom or website to share the corporate story. News releases reach journalists, consumers, bloggers & key influencers via NewMediaWire's distribution channels, ultimately increasing the audience engagement.
Visit: http://app.newmediawire.com/